detox/neoplasms

FIELD OF THE INVENTION The invention relates to the field of cancer. In particular it relates to the areas of diagnostics and lung cancer. BACKGROUND OF THE INVENTION Lung cancer is the leading cause of cancer death worldwide and NSCLC accounts for nearly 80% of the disease (1). Based on cell

FIELD OF THE INVENTION The invention relates to the field of cancer. In particular it relates to the areas of diagnostics and lung cancer. BACKGROUND OF THE INVENTION Lung cancer is the leading cause of cancer death worldwide and NSCLC accounts for nearly 80% of the disease (1). Based on cell

FIELD OF THE INVENTION The present invention relates to the field of cancer therapy. In particular, the invention provides novel compositions and methods for protecting non-neoplastic cells from the toxic effects of radiotherapy and cancer chemotherapeutic agents. BACKGROUND OF THE INVENTION Several

FIELD OF THE INVENTION The present invention relates to the field of cancer therapy. In particular, the invention provides novel compositions and methods for protecting non-neoplastic cells from the toxic effects of radiotherapy and cancer chemotherapeutic agents. BACKGROUND OF THE INVENTION Several

FIELD OF THE INVENTION The present invention relates to the field of cancer therapy. In particular, the invention provides novel compositions and methods for protecting non-neoplastic cells from the toxic effects of radiotherapy and cancer chemotherapeutic agents. BACKGROUND OF THE INVENTION Several

FIELD OF THE INVENTION This invention relates to selective peptidyl inhibitors of cancer procoagulant (CP), a protein elaborated by malignant, but not normal, animal and human cells, and to the use of these selective peptidyl inhibitors in cancer therapy and in CP removal from blood. BACKGROUND OF

BACKGROUND OF THE INVENTION I. Field of the Invention The present invention relates generally to the field of anti-cancer therapy. More particularly, it provides organic arsenic compounds and methods for their use in treating cancers such as leukemia. II. Description of Related Art Despite progress

I. Field of the Invention The present invention relates generally to the field of anti-cancer therapy. More particularly, it provides organic arsenic compounds and methods for their use in treating cancers such as leukemia. II. Description of Related Art Despite progress in leukemia therapy, most

BACKGROUND OF THE INVENTION I. Field of the Invention The present invention relates generally to the field of anti-cancer therapy. More particularly, it provides organic arsenic compounds and methods for their use in treating cancers such as leukemia. II. Description of Related Art Despite progress

PRIORITY The present application claims the benefit of Indian Provisional Patent Application No. 1838/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/050917 filed on 4 Feb. 2013, the entire disclosure of which is relied on for all purposes and is incorporated into this

FIELD OF THE INVENTION This invention relates to new macrocyclic chelants and metal chelates thereof, methods of preparing the chelants and metal chelates, and pharmaceutical compositions comprising the macrocyclic chelants and metal chelates. This invention relates particularly to the use of the